Navigation Links
Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
Date:6/26/2012

MOUNTAIN VIEW, Calif., June 26, 2012 /PRNewswire/ -- Based on its recent analysis of the clinical diagnostics market,  Frost & Sullivan recognizes GenPath Diagnostics, a business unit of BioReference Laboratories, Inc. with the 2012 North American Frost & Sullivan Award for Company of the Year. As a BioReference specialized cancer laboratory, GenPath is a major factor to the Company's impressive growth trajectory—18 years of 20% Compound Annual Growth Rate (CAGR) in revenue.

GenPath provides complete cancer laboratory testing in addition to novel and proprietary tests. With the entire cancer workup conducted in-house, GenPath delivers superior turn-around-time compared to other commercial laboratories. In addition to standard analysis including morphological examination, flow cytometry, and advanced stains, GenPath also offers proprietary cancer diagnostic testing like the OnkoMatch™ solid tumor genotyping test.

OnkoMatch™ is the culmination of state-of-the-art cancer research and provides oncologists actionable information. Patients are matched with open clinical trials based on their tumor profile. "OnkoMatch™ clearly meets an unmet need in lung cancer patients and also benefits other solid tumor cancers, "said Frost & Sullivan Industry Analyst Winny Tan.

GenPath exclusively licensed the tumor genotyping technology and protocol—upon which OnkoMatch™ is based—from leading cancer research center Massachusetts General Hospital and is the first and only commercial laboratory to offer the test nationally. OnkoMatch™ bridges widely-used single mutation tests with the future of highly complex testing, like whole genome sequencing that is anticipated to reach the clinical markets in the next few years.

Frost & Sullivan independent benchmarking across market participants concludes that the OnkoMatch™ test provides tremendous value by profiling 14 relevant oncogene
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan
2. Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
3. Frost & Sullivan Recognizes iCubate for Developing the New Gold Standard Instrument in the PCR Market
4. Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations, Says Frost & Sullivan
5. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
6. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
9. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
10. Fifth Cycle of Probiotics & Microbiota Research Grant Announced
11. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 zFlo Motion , a US ... an exciting product from a new partner. STT-Systems ... the past 15 years, with offerings in the optical-motion capture, ... IMU system (inertial measurement unit), iSen, is opening eyes around ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Global Compliance Service for Controlled Substances to Expand to China 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... by allowing for diversity of research,approaches while also encouraging sharing of IP, ... ... to result from reduced complexity, elimination of ... be maintained; South San Francisco,site to operate as an independent research and ...
... ev3 Inc. (Nasdaq:,EVVV) will release its 2008 second quarter ... regular market trading hours., The company will host ... a.m. Central Time (8:30 a.m. Eastern Time). ev3 management ... followed by a,question and answer session., The conference ...
... Apo-Al/HDL drug to be highlighted, TSX Exchange ... Resverlogix Corp.,("Resverlogix" or the "Company") (TSX:RVX) is pleased ... in an article titled,"Emerging Antidyslipidemic Drugs", which appears ... Drugs, a well respected scientific journal for,the pharmaceutical ...
Cached Biology Technology:Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 2Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 3Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 4Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 5Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 6Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 7Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 8Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 9Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 10Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 11Roche Makes Offer to Acquire All Outstanding Shares of Genentech for US$89.00 Per Share in Cash 12ev3 Inc. to Report 2008 Second Quarter Financial Results and Host Conference Call on August 1, 2008 2Resverlogix's Lead Drug Featured in Key Scientific Publication 2
(Date:1/22/2015)... 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is ... the State of Washington,s Department of ... enrollment and central issuance system for driver,s licenses and identification ... project planning and development will start in January 2015, with ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... The Wistar Institute shows how our cells create alternate versions ... genes are associated with multiple gene promoters, the researchers say, ... gene, for example, can be made with the same genetic ... Research, available online now, show how genes are read in ...
... Networks of biologically-connected marine protected areas need to be ... of marine fish larvae that take them from one ... Research published today in the international journal Oecologia sheds ... their larval stages, important information for the effective design ...
... American Association for Cancer Research has been the premier ... This year, Elizabeth H. Blackburn, Ph.D., the immediate ... laureate, will chair the Second AACR Conference on Frontiers ... research leaders from across the globe to encourage and ...
Cached Biology News:Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 2Multiple 'siblings' from every gene: Alternate gene reading leads to alternate gene products 3Data revealing migrations of larval reef fish vital for designing networks of marine protected areas 2
geminin, DNA replication inhibitor...
Normal human serum, single donor...
One-step, microplate or cuvet, colorimetric, linear detection range 0.1 mg/dL to 100 mg/dL. Procedure: 20 min....
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Biology Products: